Upregulated long noncoding RNA PANDAR predicts an unfavorable prognosis and promotes tumorigenesis in cholangiocarcinoma

• Main Authors: Xu Y, Jiang X, Cui Y
• Format: Article
• Language: English
• Published: Dove Medical Press 2017-06-01
• Series: OncoTargets and Therapy
• Subjects: cholangiocarcinoma; lncRNA; PANDAR; prognosis; tumorigenesis
• Online Access: https://www.dovepress.com/upregulated-long-noncoding-rna-pandar-predicts-an-unfavorable-prognosi-peer-reviewed-article-OTT

Yi Xu,1,2 Xingming Jiang,1 Yunfu Cui1 1Department of Hepatopancreatobiliary Surgery, Second Affiliated Hospital of Harbin Medical University, 2The Key Laboratory of Myocardial Ischemia, Harbin Medical University, Ministry of Education, Harbin, People’s Republic of China Abstract: Cholangiocarcinoma (CCA) is one of the most malignant human cancers with increasing incidence worldwide. LncRNAs have emerged as gene regulators and prognostic biomarkers in a variety of neoplasms. PANDAR, a novel cancer-related lncRNA, has been reported to be upregulated in diverse human carcinomas. In this study, we aimed to investigate the clinical significance of lncRNA PANDAR in CCA and explore its functional roles in CCA cells including cell proliferation, apoptosis, migration, invasion and epithelial-to-mesenchymal transition (EMT). The results showed that PANDAR was significantly upregulated in CCA ­tissue specimens and cell lines, and its high expression was closely associated with lymph node invasion (P=0.004), TNM stage (P=0.034) and postoperative relapse (P=0.006) in patients with CCA. Thus, overexpression of PANDAR could serve as an independent prognostic biomarker of CCA. Furthermore, silencing of PANDAR followed by siRNA significantly inhibited cell proliferation and increased apoptosis in CCA cells. In addition, suppression of PANDAR impaired migration and invasion capacity in vitro partly by affecting EMT. Overall, our findings showed that lncRNA PANDAR serves as a novel prognostic biomarker and therapeutic target for CCA. Keywords: cholangiocarcinoma, lncRNA, PANDAR, prognosis, tumorigenesis